Danish biotech firm Bavarian Nordic has proposed the re-election of four board members and the appointment of three new directors ahead of its annual general meeting on April 21.
Montse Montaner is set to step down from the board, while Charl van Zyl, Hans Martin Smith, and Svend Andersen have been nominated as new members. Additionally, a shareholder has nominated Lars Wismann, a proposal the board does not support.
Andersen previously held executive roles at companies including Perrigo and currently serves on the board of the Lundbeck Foundation. Van Zyl was formerly Head of Neurology & EU/International Markets at UCB Biopharm and is the current CEO of Lundbeck. Smith, a former CFO of Vestas, is currently the CEO of VKR Holding and serves on the board of Schouw & Co.
Mr. Charl van Zyl is an Executive Vice President-Neurology Solutions at UCB SA. He is on the Board of Directors at Ra Pharmaceuticals, Inc. and UCB Celltech. Mr. van Zyl was previously employed as an Executive Vice President by BSN Medical SA, an Executive Vice President & Commercial Leader-EMEA by Bausch & Lomb Holdings, Inc., an Executive Vice President by Bausch + Lomb, Inc., a Chief Executive Officer by JADO Technologies GmbH, a Head-Sales & Marketing by Novartis AG, and a Marketing Manager by Eli Lilly & Co. He received his undergraduate degree from the University of Cape Town.
Bavarian Nordic A/S specializes in the development, manufacturing and commercialization of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases.
Net sales by revenue source are divided between sales of products (97,2%) and services (2,8%).
Net sales are distributed geographically as follows: the United States (43.2%), Germany (18.6%), France (11.6%), Canada (3.6%), THE United Kingdom (3.4%), Finland (2.9%), Singapore (2.2%), Switzerland (1.7%), Australia (1.3%), Saudi Arabia (1.2%), Spain (0.6%), and others (9.7%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
![Charl van Zyl](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
